Advertisement
U.S. markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.13+0.03 (+0.30%)
At close: 04:00PM EDT
10.14 +0.01 (+0.10%)
After hours: 07:25PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close10.10
Open10.13
Bid10.11 x 300
Ask10.14 x 300
Day's Range10.02 - 10.34
52 Week Range7.72 - 27.48
Volume680,874
Avg. Volume1,100,229
Market Cap1.368B
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-4.59
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VIR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vir Biotechnology, Inc.
    VIR: What does Argus have to say about VIR?VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • InvestorPlace

    From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

    Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely. Regardless of the market conditions, though, the massive long-term growth runway for the biotech industry is tough to deny. The demand for better healthcare outcomes is growing, and with strengthening product pipelines, it’s best to increase your ex

  • InvestorPlace

    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

    Since Bill Gates left his position with Microsoft (NASDAQ:MSFT) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest. Gates was one of the loudest voices during the Covid-19 pandemic for providing therapeutics to poor countries and elsewhere. His Bill and Melinda Gates Foundation used its clout to influence response to the disease by governments around the world. The Foundation also gave more than $1 billion to the World Health Organiza

  • Business Wire

    Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

    SAN FRANCISCO, March 05, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the